Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma-Reference-Cited by-同舟云学术

Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma

Published:2019-02-21 Issue:3 Volume:37 Page:531-537
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Akiyama Norimichi,Karayama Masato,Inui Naoki^ORCID,Yasui Hideki,Hozumi Hironao,Suzuki Yuzo,Furuhashi Kazuki,Fujisawa Tomoyuki,Enomoto Noriyuki,Nakamura Yutaro,Inami Nao,Matsuura Shun,Kaida Yusuke,Uto Tomohiro,Matsui Takashi,Asada Kazuhiro,Matsuda Hiroyuki,Fujii Masato,Toyoshima Mikio,Suda Takafumi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-019-00747-x/fulltext.html

Reference36 articles.

1. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v1–v27. https://doi.org/10.1093/annonc/mdw326

2. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G (2017) Systemic therapy for stage IV non–small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 35:3484–3515. https://doi.org/10.1200/JCO.2017.74.6065

3. Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K (2010) Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol 5:540–545. https://doi.org/10.1097/JTO.0b013e3181d3504d

4. Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y et al (2011) Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol 6:365–371. https://doi.org/10.1097/JTO.0b013e3181fff142

5. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer. J Clin Oncol 31:2895–2902. https://doi.org/10.1200/JCO.2012.47.1102

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cu²⁺–Citrate–Chitosan Complex Nanoparticles for the Chemodynamic Therapy of Lung Cancer;ACS Omega;2024-02-09

2. Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives;Cancer Letters;2023-03

3. Amyloid precursor protein and its phosphorylated form in non-small cell lung carcinoma;Pathology - Research and Practice;2019-08